UroGen Pharma Ltd. Ordinary Shares (URGN)

Price$24.92

Favorite Metrics

Price vs S&P 500 (26W)41.80%

Price vs S&P 500 (4W)35.91%

Market Capitalization$1.21B

All Metrics

Book Value / Share (Quarterly)$0.60

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)19.48%

Cash Flow / Share (Quarterly)$-3.37

Price vs S&P 500 (YTD)2.47%

Gross Margin (TTM)88.66%

Net Profit Margin (TTM)-139.81%

EPS (TTM)$-3.20

10-Day Avg Trading Volume0.85M

EPS Excl Extra (TTM)$-3.20

Revenue Growth (5Y)56.22%

EPS (Annual)$-3.19

ROI (Annual)-1319.29%

Gross Margin (Annual)88.66%

Net Profit Margin (5Y Avg)-161.00%

Cash / Share (Quarterly)$2.49

Revenue Growth QoQ (YoY)54.03%

ROA (Last FY)-76.57%

Revenue Growth TTM (YoY)21.45%

EBITD / Share (TTM)$-2.99

ROE (5Y Avg)-324.81%

Operating Margin (TTM)-113.73%

Cash Flow / Share (Annual)$-3.37

P/B Ratio47.55x

P/B Ratio (Quarterly)20.96x

Net Income / Employee (Annual)$-1

EV / Revenue (TTM)11.20x

Net Interest Coverage (TTM)-15.36x

ROA (TTM)-72.93%

EPS Incl Extra (Annual)$-3.19

Current Ratio (Annual)4.01x

Quick Ratio (Quarterly)3.34x

3-Month Avg Trading Volume0.78M

52-Week Price Return157.70%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$-1.36

P/S Ratio (Annual)11.05x

Asset Turnover (Annual)0.55x

52-Week High$30.00

Operating Margin (5Y Avg)-122.99%

EPS Excl Extra (Annual)$-3.19

CapEx CAGR (5Y)-25.03%

26-Week Price Return48.69%

Quick Ratio (Annual)3.34x

13-Week Price Return27.53%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.01x

Enterprise Value$1,229.377

Revenue / Share Growth (5Y)33.32%

Asset Turnover (TTM)0.52x

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)0.97x

Pretax Margin (Annual)-139.74%

Cash / Share (Annual)$2.49

3-Month Return Std Dev62.79%

Gross Margin (5Y Avg)88.98%

Net Income / Employee (TTM)$-1

ROE (Last FY)-1319.29%

Net Interest Coverage (Annual)-15.36x

EPS Basic Excl Extra (Annual)$-3.19

Receivables Turnover (TTM)4.11x

Total Debt / Equity (Quarterly)4.77x

EPS Incl Extra (TTM)$-3.20

Receivables Turnover (Annual)4.11x

ROI (TTM)-41.46%

P/S Ratio (TTM)11.05x

Pretax Margin (5Y Avg)-158.27%

Revenue / Share (Annual)$2.28

Tangible BV / Share (Annual)$-3.86

Price vs S&P 500 (52W)123.07%

Year-to-Date Return6.40%

5-Day Price Return17.44%

EPS Normalized (Annual)$-3.19

ROA (5Y Avg)-70.37%

Net Profit Margin (Annual)-139.81%

Month-to-Date Return38.60%

Cash Flow / Share (TTM)$-4.08

EBITD / Share (Annual)$-2.99

Operating Margin (Annual)-113.73%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-324.81%

LT Debt / Equity (Quarterly)4.77x

EPS Basic Excl Extra (TTM)$-3.20

P/B Ratio (Annual)25.38x

Inventory Turnover (TTM)0.97x

Pretax Margin (TTM)-139.74%

Book Value / Share (Annual)$0.37

Price vs S&P 500 (13W)25.15%

Beta1.59x

P/FCF (Annual)347.61x

Revenue / Share (TTM)$2.23

ROE (TTM)-204.47%

52-Week Low$3.42

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.21

Industry Peers — Pharmaceuticals(308)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
URGNUroGen Pharma Ltd. Ordinary Shares	11.05x	21.45%	88.66%	—	$24.92
LLYEli Lilly & Co.	13.45x	44.70%	83.04%	27.59%	$919.90
JNJJohnson & Johnson	5.82x	7.87%	67.95%	14.90%	$230.69
ABBVABBVIE INC.	5.97x	8.57%	71.62%	-2.88%	$203.71
MRKMerck & Co., Inc.	4.51x	1.31%	78.55%	21.23%	$117.10
AZNAstraZeneca PLC	5.39x	8.63%	81.31%	21.88%	$200.69
NVSNovartis AG	4.87x	8.91%	75.82%	15.26%	$150.99
NVONovo-Nordisk A/S	3.74x	6.43%	80.98%	20.66%	$40.46
ABTAbbott Laboratories	3.71x	6.59%	56.50%	8.20%	$96.00
PFEPfizer Inc.	2.50x	-1.64%	75.81%	-3.51%	$27.52
BMYBristol-Myers Squibb Co.	2.52x	-0.22%	72.63%	—	$59.13

About

UroGen Pharma is a biopharmaceutical company specializing in non-muscle invasive urothelial cancer treatments. The company commercializes two FDA-approved products—Jelmyto and Zusduri (both mitomycin-based)—which leverage its proprietary RTGel sustained-release technology to enhance therapeutic efficacy. Revenue is derived from United States sales of these approved oncology products.